Dr Jennifer Chan speaks to ecancer at ESMO 2023 about the Alliance A021602 study.
This was a phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumours after progression on prior therapy.
The results show cabozantinib as having a statistically significant and clinically meaningful improvement in progression free survival in extra-pancreatic neuroendocrine tumours and pancreatic neuroendocrine tumours. Cabozantinib may be a new treatment option for patients with previously treated, progressive neuroendocrine tumours.